Kaouthar Lbiati Net Worth

What's Kaouthar Lbiati's mailing address?

Kaouthar's mailing address filed with the SEC is C/O HEPION PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON, NJ, 08837.

Insiders trading at Hepion Pharmaceuticals Inc

Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard и John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.

What does Hepion Pharmaceuticals Inc do?

hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.

Hepion Pharmaceuticals Inc executives and stock owners

Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Robert Foster,
  Chief Executive Officer, Chief Scientific Officer, Director
• Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.,
  Pres, CEO & Director
• Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D.,
  Pres, CEO & Director
• John T. Cavan,
  Chief Financial Officer
• John Cavan,
  Chief Financial Officer
• John Brancaccio,
  Independent Director
• Timothy Block,
  Independent Director
• Arnold Lippa,
  Independent Director
• Thomas Adams,
  Independent Director
• Gary Jacob,
  Chairman of the Board
• Stephen Kilmer,
  IR Contact Officer
• Peter Wijngaard,
  Independent Director
• Dr. Stephen A. Harrison,
  Member of Scientific Advisory Board & Consultant Medical Director
• Dr. John Z. Sullivan-Bolyai,
  Part-Time Consultant
• Dr. Todd M. Hobbs M.D.,
  Chief Medical Officer
• Dr. Patrick Mayo Ph.D.,
  Sr. VP of Clinical Pharmacology
• Dr. Daniel Trepanier Ph.D.,
  Sr. VP of Drug Devel.
• Sharen Pyatetskaya,
  Director of Investor Relations
• Dr. Daren Ure Ph.D.,
  Chief Scientific Officer
• Michael J. Purcell,
  Director
• Kaouthar Lbiati,
  Director